Pub Date : 2024-01-11DOI: 10.2174/0122113525284634231222071749
Ami Febriza, H. Idrus, V. Kasim
Lipopolysaccharides (LPS) from Salmonella typhi will attach with Toll-Like Receptor 4 (TLR-4) and trigger an inflammatory response to fight the pathogen. Due to infection, the HMGB1 is produced by immune cells or secreted passively from dead cells. Fur-thermore, the antimicrobial peptide, cathelicidin was secreted to neutralize and eliminate these path-ogens. This study aims to examine the interaction of Cathelicidin antimicrobial peptide (CAMP), TLR-4, and HMGB-1 on inhibiting bacterial growth in Salmonella infection. This study is an experiment that uses a pre-post-test design. Mice balb/c were separated into three groups; group A received levofloxacin for five days, group B received a placebo, and group C was the control. Both groups, A and B, received an injection of S. Typhi strain thy1. Blood samples were taken from three groups on the 4th, 10th, and 30th day to calculate CAMP, TLR-4, and HMGB-1 mRNA gene expression levels. To determine bacterial colony, peritoneal fluid was taken three times on the 4th, 10th, and 30th day to calculate bacterial colony. This study aim to examine the interaction of Cathelicidin antimicrobial peptide (CAMP), TLR-4, and HMGB-1 on inhibiting bacterial growth in Salmonella infection. Our finding observed that the expression of mRNA CAMP was inversely related to bacte-rial colony count, which means that higher CAMP mRNA expression was associated with reduced bacterial colony count in groups A and B. The expression of HMGB-1 mRNA was found to be positively correlated with bacterial growth in group A. Meanwhile, TLR-4 mRNA expression did not significantly correlate with bacterial colony count in any groups. This study is an experiment that uses a pre-post-test design. Mice balb/c were separated into three groups; group A received levofloxacin for five days, group B received a placebo, and group C was the control. Both groups, A and B, received an injection of S. Typhi strain thy1. Blood samples were taken from three groups on the 4th, 10th, and 30th day to calculate CAMP, TLR-4, and HMGB-1 mRNA gene expression levels. To determine bacterial colony, peritoneal fluid was taken three times on the 4th, 10th, and 30th day to calculate bacterial colony. CAMP, TLR-4, and HMGB-1 affect bacterial infections. Higher expression CAMP mRNA levels lower colony counts. Meanwhile, decreasing TLR-4 and HMGB-1 mRNA expression were found during the study, due to reducing growth bacteria. The expression of mRNA CAMP and bacterial colony count correlated negatively. The expression of HMGB-1 mRNA correlated with bacterial growth. Higher CAMP mRNA expression was found to relate to reduced bacterial colony count in groups A and B using linear regression.
{"title":"Exploring the Role of Cathelicidin Antimicrobial Peptide, Toll-Like Receptor 4, and HMGB-1 in Bacterial Infection","authors":"Ami Febriza, H. Idrus, V. Kasim","doi":"10.2174/0122113525284634231222071749","DOIUrl":"https://doi.org/10.2174/0122113525284634231222071749","url":null,"abstract":"\u0000\u0000Lipopolysaccharides (LPS) from Salmonella typhi will attach with Toll-Like Receptor 4 (TLR-4) and trigger an inflammatory response to fight the pathogen. Due to infection, the HMGB1 is produced by immune cells or secreted passively from dead cells. Fur-thermore, the antimicrobial peptide, cathelicidin was secreted to neutralize and eliminate these path-ogens. This study aims to examine the interaction of Cathelicidin antimicrobial peptide (CAMP), TLR-4, and HMGB-1 on inhibiting bacterial growth in Salmonella infection.\u0000\u0000\u0000\u0000This study is an experiment that uses a pre-post-test design. Mice balb/c were separated into three groups; group A received levofloxacin for five days, group B received a placebo, and group C was the control. Both groups, A and B, received an injection of S. Typhi strain thy1. Blood samples were taken from three groups on the 4th, 10th, and 30th day to calculate CAMP, TLR-4, and HMGB-1 mRNA gene expression levels. To determine bacterial colony, peritoneal fluid was taken three times on the 4th, 10th, and 30th day to calculate bacterial colony.\u0000\u0000\u0000\u0000This study aim to examine the interaction of Cathelicidin antimicrobial peptide (CAMP), TLR-4, and HMGB-1 on inhibiting bacterial growth in Salmonella infection.\u0000\u0000\u0000\u0000Our finding observed that the expression of mRNA CAMP was inversely related to bacte-rial colony count, which means that higher CAMP mRNA expression was associated with reduced bacterial colony count in groups A and B. The expression of HMGB-1 mRNA was found to be positively correlated with bacterial growth in group A. Meanwhile, TLR-4 mRNA expression did not significantly correlate with bacterial colony count in any groups.\u0000\u0000\u0000\u0000This study is an experiment that uses a pre-post-test design. Mice balb/c were separated into three groups; group A received levofloxacin for five days, group B received a placebo, and group C was the control. Both groups, A and B, received an injection of S. Typhi strain thy1. Blood samples were taken from three groups on the 4th, 10th, and 30th day to calculate CAMP, TLR-4, and HMGB-1 mRNA gene expression levels. To determine bacterial colony, peritoneal fluid was taken three times on the 4th, 10th, and 30th day to calculate bacterial colony.\u0000\u0000\u0000\u0000CAMP, TLR-4, and HMGB-1 affect bacterial infections. Higher expression CAMP mRNA levels lower colony counts. Meanwhile, decreasing TLR-4 and HMGB-1 mRNA expression were found during the study, due to reducing growth bacteria.\u0000\u0000\u0000\u0000The expression of mRNA CAMP and bacterial colony count correlated negatively. The expression of HMGB-1 mRNA correlated with bacterial growth. Higher CAMP mRNA expression was found to relate to reduced bacterial colony count in groups A and B using linear regression.\u0000","PeriodicalId":7951,"journal":{"name":"Anti-Infective Agents","volume":"43 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139533381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-09DOI: 10.2174/0122113525272349231210055403
Rashmi Saini, Mohammad I. Ali, Maya Pant, Ashish Warghane
Natural substances have been the principal source of medications since antiquity. Natural goods are gaining popularity as a source of novel medications. This article investigates a variety of variables like plant, marine, and microbial sources that contribute to the growing interest in natural goods as a source of novel medications. Viruses have remained resistant to treatment and prevention for a longer period than other forms of life. Viral diseases can currently only be treated with a limited number of drugs. Significant research initiatives have been committed to identifying novel antiviral natural compounds to fight viruses that harm people, plants, insects, animals, fungi, and microbes. A recent study of the prevalence and sources of antiviral medications licensed by the Food and Drug Administration (FDA) has focused on natural products. Out of the estimated 250,000 higher plant species, only 5 to 15 percent have been thoroughly evaluated for the existence of bioactive substances in them, and the ability of the other species has hardly been investigated. This review aims to offer an overview of the crucial role played by natural products in the discovery and development of novel antiviral drugs with potent antiviral activity, including phytochemicals such as carbohydrates, coumarins, flavonoids, chromones, alkaloids, lignans, phenols, tannins, proteins, peptides, antiviral plant extracts, other marine, and microbial sources.
{"title":"Current Status of Potential Antiviral Drugs Derived from Plant, Marine,\u0000and Microbial Sources","authors":"Rashmi Saini, Mohammad I. Ali, Maya Pant, Ashish Warghane","doi":"10.2174/0122113525272349231210055403","DOIUrl":"https://doi.org/10.2174/0122113525272349231210055403","url":null,"abstract":"\u0000\u0000Natural substances have been the principal source of medications since antiquity.\u0000Natural goods are gaining popularity as a source of novel medications. This article investigates a variety of variables like plant, marine, and microbial sources that contribute to the\u0000growing interest in natural goods as a source of novel medications. Viruses have remained\u0000resistant to treatment and prevention for a longer period than other forms of life. Viral diseases can currently only be treated with a limited number of drugs. Significant research initiatives have been committed to identifying novel antiviral natural compounds to fight viruses\u0000that harm people, plants, insects, animals, fungi, and microbes. A recent study of the prevalence and sources of antiviral medications licensed by the Food and Drug Administration\u0000(FDA) has focused on natural products. Out of the estimated 250,000 higher plant species,\u0000only 5 to 15 percent have been thoroughly evaluated for the existence of bioactive substances\u0000in them, and the ability of the other species has hardly been investigated. This review aims to\u0000offer an overview of the crucial role played by natural products in the discovery and development of novel antiviral drugs with potent antiviral activity, including phytochemicals such\u0000as carbohydrates, coumarins, flavonoids, chromones, alkaloids, lignans, phenols, tannins,\u0000proteins, peptides, antiviral plant extracts, other marine, and microbial sources.\u0000","PeriodicalId":7951,"journal":{"name":"Anti-Infective Agents","volume":" 31","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139628514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}